Online inquiry

IVTScrip™ mRNA-Anti-TNFRSF17, C11D5.3 scFv-8A-F9Z CAR(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (CAT#: GTTS-WQ4907MR)

This product GTTS-WQ4907MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets TNFRSF17 gene. The antibody can be applied in Multiple myeloma (MM) research.

Specifications
Product type	mRNA
Modified bases	5-Methyl-CTP & Pseudo-UTP
5' Cap	Cap 0
Species	Chimeric
RefSeq	NM_001192.3
Applications	Gene therapy research
Format	Powder
Quantity	100 µg
Purification	oligo-dT affinity purification

Target Gene
Gene ID	608
UniProt ID	Q02223

Download
Download resources about mRNA therapeutics development to boost your research.

CUSTOMER REVIEWS and Q&As
There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFRSF17, C11D5.3 scFv-8A-F9Z CAR(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ4907MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT	Product Name	Product Type	CDs
GTTS-WQ10947MR	IVTScrip™ mRNA-Anti-HAVCR2, MBG-453(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))	mRNA	MBG-453
GTTS-WQ4954MR	IVTScrip™ mRNA-Anti-GP, c13C6-FR1-N(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))	mRNA	c13C6-FR1-N
GTTS-WQ8662MR	IVTScrip™ mRNA-Anti-CD38, HuMax-CD38(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))	mRNA	HuMax-CD38
GTTS-WQ1848MR	IVTScrip™ mRNA-Anti-IL17A, AG1-25(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))	mRNA	AG1-25
GTTS-WQ13813MR	IVTScrip™ mRNA-Anti-S, REGN-10987(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))	mRNA	REGN-10987
GTTS-WQ2873MR	IVTScrip™ mRNA-Anti-CCR4, AMG-761(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))	mRNA	AMG-761
GTTS-WQ9962MR	IVTScrip™ mRNA-Anti-hly, KBSA301(Cap 1, 2-Thio-UTP, 30 nt-poly(A))	mRNA	KBSA301
GTTS-WQ7689MR	IVTScrip™ mRNA-Anti-CD3E&MS4A1, GEN3013(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))	mRNA	GEN3013

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST